Market Research Reports, Inc. has announced the addition of “Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation” research report to their offering. See more at- http://mrr.cm/Zmc

1. www.MarketResearchReports.com
Category : Pharma & Healthcare
All logos and Images mentioned on this slide belong to their respective owners.

2. www.MarketResearchReports.com
Introduction to Report
 Launch Date: June 30, 2014
 Number of Pages: 77
 Geography Coverage: Global
 Available Format: PDF
Price For Single User License: USD 3,500
Price For Site User License: USD 7,000
Price For Global User License: USD 10,500
Delivery Time: Within 24 Hours (During Working Days)

3. www.MarketResearchReports.com
About the Report
“Frontier Pharma: Psoriasis Identifying and
Commercializing First-in-Class Innovation”, which
identifies and assesses first-in-class innovation in the
psoriasis development pipeline.
Despite mostly targeting established molecules, the
psoriasis pipeline is showing a high level of innovation in
first-in-class molecules, including novel angiogenic drugs,
growth factors, chaperone proteins and cytokines,
according to Frontier Pharma: Psoriasis - Identifying and
Commercializing First-in-Class Innovation report.

4. www.MarketResearchReports.com
Research Findings
This report states that first-in-class programs constitute
an estimated 27% of the entire psoriasis pipeline, and are
predominantly composed of targeted therapies, including
cytokine and receptor modulators, nuclear receptor
modulators and intracellular kinase inhibitors.
There are several novel therapies targeting first-in-class T
cell antigens, thanks to a growing understanding of the
signaling pathways underlying the psoriasis
pathophysiology, in which T cells have been shown to play
a substantial role in disease progression.
Therapies that can selectively modulate specific subsets
of immune cells, without compromising the entire
immune system, have become increasingly desirable,
according to Publisher.

5. www.MarketResearchReports.com
Research Findings Continues…
One such program is Tregalizumab, a humanized Cluster
of Differentiation (CD) 4-specific monoclonal antibody.
In contrast to other anti-CD4 antibodies, Tregalizumab is
able to activate the suppressive properties of regulatory T
cells. It is currently in Phase II clinical trials for the
treatment of rheumatoid arthritis and in Preclinical
development for treating psoriasis.
Publisher states that although no preclinical or clinical
efficacy data has been disclosed for the antibody, it has
been involved in a lucrative co-development deal worth
$480 million between Biotest and Abbott Laboratories.

6. www.MarketResearchReports.com
Scope
A brief introduction to psoriasis, including symptoms,
pathophysiology, and overview of pharmacotherapy
The changing molecular target landscape between
market and pipeline and particular focal points of
innovation
Overview of how innovative products are contributing to
the pipeline and market for psoriasis
Comprehensive review of the pipeline for first-in-class
therapies, analyzed on the basis of phase distribution,
molecule type, molecular target, and administration route
Identification and assessment of first-in-class molecular
targets with a particular focus on early-stage programs of
which clinical utility has yet to be evaluated, as well as
literature reviews on novel molecular targets

7. www.MarketResearchReports.com
Reasons To Buy
Understanding of the focal shifts in molecular targets in
the psoriasis pipeline
Understanding of the distribution of pipeline programs
by phase of development, molecule type and molecular
target
Scientific and clinical analysis of first-in-class
developmental programs
Assessment of the valuations of licensed and co-
developed psoriasis treatments
A list of the first-in-class therapies potentially open to
deal-making opportunities.
Analysis of financial valuations on licensed or co-
developed first-in-class therapies and generics

8. www.MarketResearchReports.com
Report Coverage
1. The Case for Innovation
2. Clinical and Commercial Landscape
3. Assessment of Psoriasis Pipeline and Innovation
4. First-in-Class Target and Pipeline Program Evaluation
5. Deals and Strategic Consolidations
6. Appendix
For more details regarding Report coverage see the last slide
All logos and Images mentioned on this slide belong to their respective owners.

9. www.MarketResearchReports.com
Custom Research:
 Are you an industry professional, entrepreneur,
venture capitalist, investors and organization, then let
us know your specific research requirements. Our goal
is to cater to your requirements be it for a custom
market research project, syndicated research report on
a specific market or industry sector, newsletter creation,
case study development or anything else related to
marketing research.
For Any Customization Related query Visit IdeaCenter @
http://www.marketresearchreports.com/idea-center

10. www.MarketResearchReports.com
How To Buy This Report?
Visit following URL to see Table of Content and
purchase this publication:
http://mrr.cm/Zmc
About Market Research Reports, Inc.
Market Research Reports provides a customized set
of reports from reputed Publishers, built on the
intelligence available within organizations and
leverages on our motto of “Intelligence Redefined”.
Contact : Amitava Sen
Email : info@marketresearchreports.com
Phone: +1 302-703-7787 (USA) +91-8762746600 (India)